Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Prostatic Neoplasms 6Ovarian Neoplasms 6Breast Neoplasms 3Prostatic Neoplasms, Castration-Resistant 2Neoplasm Metastasis 2Fallopian Tube Neoplasms 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1SCLC,Extensive Stage 1Pathologic Complete Response 1Ovarian Carcinosarcoma 1Oropharyngeal Neoplasms 1Neoplasms 1Mouth Neoplasms 1Metastatic Castration-sensitive Prostate Cancer 1Laryngeal Diseases 1Hereditary Sensory and Autonomic Neuropathies 1Hemangiosarcoma 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Ovarian Epithelial 1Biliary Tract Neoplasms 1

Interventions

Fulvestrant 2tivozanib 1ribociclib 1palbociclib 1niraparib 1lorlatinib 1exemestane 1encorafenib 1cemiplimab 1binimetinib 1abemaciclib 1Tamoxifen 1STX-478 1Metformin 1Letrozole 1Imlunestrant 1Cetuximab 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × niraparib × 30 days × Clear all
NCT06433219 2026-06-03

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

EMD Serono

Phase 2 Active not recruiting
63 enrolled
Gynecologic

Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡